EN HU

Department of Clinical Oncology

Department of Clinical Oncology
Department of Clinical Oncology
Uploaded publications:
84
Publications in DEA:
84
OA:
54
Date range:
2019-2025
2025
1.
Hajdu, E., Molnár, É., Molnárné Rázsó, K., Schlammadinger, Á., Árokszállási, A., Lukács, C. G., Fülesdi, B., Bereczky, Z., Oláh, Z.: A Modified Viscoelastic Point-of-Care Method for Rapid Quantitative Detection of Enoxaparin: a Single-Centre Observational Study.
J Clin Med. 14 (4), 1-13, (article identifier: 1328), 2025.
Journal metrics:
Q1 Medicine (miscellaneous) (2024)
2.
Király, J., Berzi, A., El-Kareh, R., Sebestyén, E., Ujvárosy, D., Emri, M., Bhattoa, H. P., Kappelmayer, J., Miller, K. E., Tóth, G.: Breaking the guidelines: how financial unawareness fuels guideline deviations and inefficient DVT diagnostics.
Diagnosis 12 (2), 232-240, 2025.
Journal metrics:
Q2 Biochemistry (medical) (2024)
Q2 Clinical Biochemistry (2024)
Q2 Health Policy (2024)
Q2 Medicine (miscellaneous) (2024)
Q2 Public Health, Environmental and Occupational Health (2024)
3.
Sebestyén, E., Csige, D., Antal-Szalmás, P., Horváth, Á., Végh, E., Soós, B., Pethő, Z., Bodnár, N., Hamar, A. B., Bodoki, L., Kacsándi, D., Földesi, R., Kalina, E., Nagy, G., Kerekes, G., Nagy, B. J., Hódosi, K., Szamosi, S., Árkosy, P., Szűcs, G., Szekanecz, Z., Szekanecz, É.: Effects of Tofacitinib Therapy on Circulating Tumour-Associated Antigens and Their Relationship with Clinical, Laboratory and Vascular Parameters in Rheumatoid Arthritis.
Biomolecules. 15 (5), 1-15, (article identifier: 648), 2025.
Journal metrics:
Q1 Biochemistry (2024)
Q2 Molecular Biology (2024)
4.
Géczi, D., Klekner, Á., Balogh, I., Penyige, A., Szilágyi, M., Virga, J., Bakó, A., Nagy, B., Torner, B., Hádáné Birkó, Z.: Identification of Deregulated miRNAs and mRNAs Involved in Tumorigenesis and Detection of Glioblastoma Patients Applying Next-Generation RNA Sequencing.
Pharmaceuticals. 18 (3), 1-29, (article identifier: 431), 2025.
Journal metrics:
Q1 Drug Discovery (2024)
Q2 Molecular Medicine (2024)
Q1 Pharmaceutical Science (2024)
5.
Koshkin, V. S., Danchaivijitr, P., Bae, W. K., Semenov, A., Ozyilkan, O., Su, Y. L., Arranz Arija, J., Tsujihata, M., Bögemann, M., Hendriks, M. P., Delgado, S. N., Rosenbaum, E., Lopez, K. A., Bavle, A., Liu, C. C., Imai, K., Furka, A.: Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
Eur. Urol. 87 (4), 390-395, 2025.
Journal metrics:
D1 Urology (2024)
6.
Ngo, M. T., Nagy, T., Szoboszlai, Z., Csikos, C., Dénes, N., Furka, A., Trencsényi, G., Garai, I.: The Relationship of Metabolic Activity and αvβ3 Receptor Expression in Aggressive Breast Cancer Subtypes Tumors: a Preliminary Report.
In Vivo. 39 (1), 160-171, 2025.
Journal metrics:
Q2 Biochemistry, Genetics and Molecular Biology (miscellaneous) (2024)
Q3 Cancer Research (2024)
Q2 Medicine (miscellaneous) (2024)
Q3 Pharmacology (2024)
7.
Lengyel, M., Molnár, Á., Nagy, T., Jdeed, S., Garai, I., Horváth, Z., Uray, I. P.: Zymogen granule protein 16B (ZG16B) is a druggable epigenetic target to modulate the mammary extracellular matrix.
Cancer Sci. 116 (1), 81-94, 2025.
Journal metrics:
Q2 Cancer Research (2024)
D1 Medicine (miscellaneous) (2024)
Q1 Oncology (2024)
2024
8.
Vaishampayan, U. N., Keessen, M., Dreicer, R., Heath, E. I., Buchler, T., Árkosy, P., Csőszi, T., Wiechno, P., Kopyltsov, E., Orlov, S. V., Plekhanov, A., Smagina, M., Varlamov, S., Shore, N. D.: A global phase II randomized trial comparing oral taxane ModraDoc006/r to intravenous docetaxel in metastatic castration resistant prostate cancer.
Eur. J. Cancer. 202, 1-10, (article identifier: 114007), 2024.
Journal metrics:
Q1 Cancer Research
D1 Oncology
9.
Furka, A.: Aktualitások az emlőrákkal kapcsolatosan: Szűrés és kezelések.
Med. Tribune. 22 (7), 14-15, 2024.
10.
Kostyál, L., Tornyi, I., Furka, A.: A szarkopénia mérése komputertomográfiával és jelentősége onkológiai betegeknél.
Klin. Onkol. 11 (1), 82-86, 2024.
11.
Choueiri, T. K., Powles, T., Peltola, K., de Velasco, G., Burotto, M., Suárez, C., Ghatalia, P., Iacovelli, R., Lam, E. T., Verzoni, E., Gümüş, M., Stadler, W. M., Kollmannsberger, C., Melichar, B., Venugopal, B., Gross-Goupil, M., Poprach, A., De Santis, M., Schutz, F. A., Park, S. H., Nosov, D., Porta, C., Lee, J. L., Garcia-del-Muro, X., Biscaldi, E., Manneh Kopp, R., Oya, M., He, L., Wang, A., Perini, R. F., Vickery, D., Albiges, L., Rini, B. I., LITESPARK-005 Investigators: Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
N. Engl. J. Med. 391 (8), 710-721, 2024.
12.
Varga, Z. J., Balog, K., Sebő, É., Árkosy, P., Tóth, D.: Beyond a decade: a comparative study of 15-year survival rates in screen-detected vs. symptomatic breast cancer patients in Hungary.
Irish J. Med. Sci. 193 (1), 57-63, 2024.
Journal metrics:
Q2 Medicine (miscellaneous)
13.
Szekanecz, Z., Besnyi, A., Kónya, P., Füri, J., Király, E., Bertalan, É., Falus, G., Udvardi, B., Kovács-Kis, V., Andrássy, L., Maros, G., Fancsik, T., Pethő, Z., Gomez, I., Horváth, Á., Gulyás, K., Juhász, B., Hódosi, K., Jakabné Sándor, Z., Bhattoa, H. P., Kovács, I. J.: Bones or Stones: how Can We Apply Geophysical Techniques in Bone Research?.
Int. J. Mol. Sci. 25 (19), 1-16, (article identifier: 10733), 2024.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
14.
Gulyás, A., Pinczés, L. I., Mátyus, J., Végh, E., Bedekovics, J., Tóth, J., Barna, S., Hunya, Z., Szabó, I. L., Gazdag, A., Illés, Á., Magyari, F.: Case report: targeted treatment strategies for Erdheim-Chester disease.
Front Oncol. 14, 1-6, (article identifier: 1305518), 2024.
Journal metrics:
Q2 Cancer Research
Q2 Oncology
15.
Kurdi, N., Mokánszki, A., Balogh, I., Ujfalusi, A., Szabó, S., Méhes, G., Bedekovics, J.: Extracranial metastatic oligodendroglioma with molecular progression, case presentation.
Diagn. Pathol. 19 (1), 1-8, (article identifier: 103), 2024.
Journal metrics:
Q2 Histology
Q2 Medicine (miscellaneous)
Q2 Pathology and Forensic Medicine
16.
Szivos, L., Virga, J., Mészár, Z. M., Rostás, M., Bakó, A., Zahuczky, G. J., Hortobágyi, T., Klekner, Á.: Prognostic Role of Invasion-Related Extracellular Matrix Molecules in Diffusely Infiltrating Grade 2 and 3 Astrocytomas.
Brain Sci. 14 (11), 1-17, (article identifier: 1157), 2024.
Journal metrics:
Q2 Neuroscience (miscellaneous)
17.
Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O'Shaughnessy, J. A., Wildiers, H., Pierga, J. Y., Zhang, Q., Saura, C., Biganzoli, L., Sohn, J. H., Im, S. A., Lévy, C., Jacot, W., Begbie, N., Ke, J., Patel, G., Curigliano, G., DESTINY-Breast06 Trial Investigators: Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer.
N. Engl. J. Med. 391 (22), 2110-2122, 2024.
2023
18.
Sütő, J., Klekner, Á., Nagy, J., Szemán-Nagy, A.: A műtéti felkészítés hatásának vizsgálata gerincműtétet követően = The effect of surgical psychoeducation on the outcome of spinal surgery.
Ideggyogy. Szle. 76 (1-2), 46-50, 2023.
Journal metrics:
Q4 Neurology
Q4 Neurology (clinical)
19.
Tornyi, I., Árkosy, P., Horváth, I., Furka, A.: A new perspective on the proper timing of radiotherapy during CDK4/6 inhibitor therapy in patients with "bone-only" metastatic breast cancer.
Pathol. Oncol. Res. 29, 1-8, (article identifier: 1611369), 2023.
Journal metrics:
Q3 Cancer Research
Q2 Medicine (miscellaneous)
Q2 Oncology
Q2 Pathology and Forensic Medicine
20.
Jambrovics, K., Póliska, S., Scholtz, B., Uray, I. P., Balajthy, Z.: ATO Increases ROS Production and Apoptosis of Cells by Enhancing Calpain-Mediated Degradation of the Cancer Survival Protein TG2.
Int. J. Mol. Sci. 24 (13), 1-11, (article identifier: 10938), 2023.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
21.
Bádon, E. S., Beke, L., Mokánszki, A., András, C., Méhes, G.: Carbonic Anhydrase IX Expression and Treatment Response Measured in Rectal Adenocarcinoma Following Neoadjuvant Chemo-Radiotherapy.
Int. J. Mol. Sci. 24 (3), 1-16, (article identifier: 2581), 2023.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
D1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
D1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
22.
Bádon, E. S., Mokánszki, A., Mónus, A., András, C., Méhes, G.: Clonal diversity in KRAS mutant colorectal adenocarcinoma under treatment: Monitoring of cfDNA using reverse hybridization and DNA sequencing platforms.
Mol. Cell. Probes. 67, 1-8, (article identifier: 101891), 2023.
Journal metrics:
Q3 Cell Biology
Q3 Molecular Biology
23.
Szekanecz, Z., Vokó, Z., Surján, O., Rákóczi, É., Szamosi, S., Szűcs, G., Szekanecz, É., Müller, C., Kiss, Z.: Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals.
Front. Immunol. 14, 1-8, 2023.
Journal metrics:
Q1 Immunology
Q1 Immunology and Allergy
24.
Koshkin, V. S., Danchaivijitr, P., Bae, W. K., Semenov, A., Özyilkan, Ö., Su, Y. L., Arranz Arija, J., Tsujihata, M., Boegemann, M., Hendriks, M. P., Neciosup Delgado, S. P., Cheng, S., Rosenbaum, E., Lopez, K. A., Bavle, A., Liu, C. C., Imai, K., Furka, A.: Efficacy and safety outcomes with pembrolizumab (pembro) rechallenge for patients (pts) with advanced/metastatic urothelial cancer (UC) who responded to first-course treatment.
Ann. Oncol. 34 (S2), S1211, 2023.
25.
Váradi, M., Horváth, O., Módos, O., Fazekas, T., Grunewald, C. M., Niegisch, G., Krafft, U., Grünwald, V., Hadaschik, B., Oláh, C., Maráz, A., Furka, A., Szűcs, M., Nyirády, P., Szarvas, T.: Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
Sci. Rep. 13, 1-11, (article identifier: 17378), 2023.
Journal metrics:
D1 Multidisciplinary
DEENK University of Debrecen
© 2012 University of Debrecen